Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast 2025-2034

The facioscapulohumeral muscular dystrophy epidemiology forecast suggests that facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent forms of muscular dystrophy, with the disease severity varying widely in the affected population. As per the Orphanet, the prevalence of this rare familial disease is estimated to range from 1/8,000 to 1/20,000. Additionally, facioscapulohumeral muscular dystrophy is reported to rank as the third most common form of hereditary myopathy, with the onset occurring at any age.

Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast Report Coverage

The “Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of facioscapulohumeral muscular dystrophy. It projects the future incidence and prevalence rates of facioscapulohumeral muscular dystrophy cases across various populations. The study covers age and type as major determinants of the facioscapulohumeral muscular dystrophy population. The report highlights patterns in the prevalence of facioscapulohumeral muscular dystrophy over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on facioscapulohumeral muscular dystrophy epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Facioscapulohumeral Muscular Dystrophy Understanding: Disease Overview

Facioscapulohumeral muscular dystrophy (FSHD) is a type of muscular dystrophy that primarily affects the muscles of the face, shoulders, and upper arms. It belongs to a group of inherited disorders characterized by progressive muscle weakness and degeneration. The severity of muscle weakness can vary widely between individuals, with some experiencing mild weakness, while others may develop disability over time.

Facioscapulohumeral muscular dystrophy is caused by mutations in or deletions of a specific region on chromosome 4 called the D4Z4 repeat region. Type 1 facioscapulohumeral muscular dystrophy is the most common form and involves a deletion of part of the D4Z4 region on chromosome 4. In Type 2 facioscapulohumeral muscular dystrophy, a mutation at a different locus occurs, which leads to inappropriate DUX4 expression.

Facioscapulohumeral Muscular Dystrophy Epidemiology Perspective

The facioscapulohumeral muscular dystrophy epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for facioscapulohumeral muscular dystrophy epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The facioscapulohumeral muscular dystrophy detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Various studies estimate the prevalence of facioscapulohumeral muscular dystrophy to be about 3.2 to 4.6 per 100,000, with almost no predilection towards any racial group.
• The Orphanet reports that the prevalence of facioscapulohumeral muscular dystrophy (FSHD) ranges from 1/8,000 to 1/20,000.
• Approximately 1 in 7500 individuals are affected by facioscapulohumeral muscular dystrophy, according to a research article published in Scientific Reports (2024).
• According to the Muscular Dystrophy Association, the onset of symptoms occurs before the age of 20 in about 90% of facioscapulohumeral muscular dystrophy patients.
• The severity of symptoms is highly variable among facioscapulohumeral muscular dystrophy (FSHD) patients, with nearly 20% of the affected individuals requiring a wheelchair as weakness progresses.

Country-wise Facioscapulohumeral Muscular Dystrophy Epidemiology Segment

The facioscapulohumeral muscular dystrophy epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of facioscapulohumeral muscular dystrophy varies significantly between countries due to differences in factors such as ethnic and population variability, access to healthcare and genetic testing, awareness levels of rare diseases, disease surveillance and reporting, and population age structure, among others. As per Winnen, A et al. (2022), the estimated prevalence of facioscapulohumeral muscular dystrophy ranges from 16,000 to 38,000 patients in the United States.

Facioscapulohumeral Muscular Dystrophy: Treatment Overview

Physical and occupational therapy is the primary treatment approach for facioscapulohumeral muscular dystrophy. Stretching and strengthening exercises can help prevent contractures and maintain muscle function. For pain management, facioscapulohumeral muscular dystrophy therapeutics like non-steroidal anti-inflammatory drugs (NSAIDs), pain relievers like acetaminophen, or prescription medications are used to relieve discomfort.

The application of heat or cold packs is also recommended to address muscle stiffness and soreness. In severe facioscapulohumeral muscular dystrophy cases, surgical procedures like scapulothoracic fusion (fusing the shoulder blade to the ribs) may be performed to stabilize the shoulder blade and improve arm function.

Key Questions Answered

• What are the key findings of facioscapulohumeral muscular dystrophy epidemiology in the 8 major markets?
• What will be the total number of patients with facioscapulohumeral muscular dystrophy across the 8 major markets during the forecast period?
• What was the country-wise facioscapulohumeral muscular dystrophy epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of facioscapulohumeral muscular dystrophy patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of facioscapulohumeral muscular dystrophy during the forecast period of 2025-2034?
• What are the currently available treatments in the facioscapulohumeral muscular dystrophy market?
• What are the disease risks, signs, symptoms, and unmet needs of facioscapulohumeral muscular dystrophy?

Scope of the Facioscapulohumeral Muscular Dystrophy Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of facioscapulohumeral muscular dystrophy based on several factors.
• The Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The facioscapulohumeral muscular dystrophy report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.